• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

Inflammatory Bowel Disease and Biologic Therapies in Pregnancy

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Studies on safety and outcomes with the use of biologics during pregnancy in women with inflammatory bowel disease (IBD) are limited
  • Nielsen et al. (Clinical Gastroenterology and Hepatology, 2020) estimated the prevalence of adverse pregnancy outcomes in women with IBD who are using biologic therapies

METHODS:

  • Systematic review and meta-analysis
  • Data sources
    • Major databases through June 2020
  • Inclusion criteria
    • At least one treatment group where biologics were used
    • Estimates available regarding the prevalence of adverse pregnancy outcomes when using biologics
  • Study design
    • Biologics: Anti-TNF | Anti-integrins | Anti-cytokines
    • Prevalence and relative risk (RR) were pooled using a random effects model
    • Authors assessed impact of disease activity and stratifying by type of biologic administered when possible

RESULTS:

  • 48 studies | 6,963 patients
  • Biologic therapy in IBD pregnancies was associated with the following pooled prevalences
    • Early pregnancy loss: 8% (95% CI, 6 to 10%)
    • Preterm birth: 9% (95% CI, 7 to 11%)
    • Still birth: 0% (95% CI, 0 to 0%)
    • Low birth weight: 8% (95% CI, 5 to 10%)
    • Congenital malformations: 1% (95% CI, 1 to 2%)
  • Overall, above prevalence rates comparable to general populations
  • In subgroup analyses of a small number of studies, the prevalence of early pregnancy loss and preterm birth were higher in vedolizumab (an anti-integrin) vs anti-TNF users
  • Continued TNF inhibitor use during the third trimester was not associated with risk for the following
    • Preterm birth: RR 1.41 (95% CI, 0.77 to 2.60)
    • Low birth weight: RR 1.32 (95% CI, 0.80 to 2.18)
    • Congenital malformations: RR 1.28 (95% CI, 0.47 to 3.49)

CONCLUSION:

  • Women with IBD who use biologics during pregnancy experience adverse pregnancy outcomes similar to the general population
    • Results included no evidence of increased prevalence for early pregnancy loss or stillbirth rates which were comparable to those seen in women with IBD and the general population
  • The authors conclude that

…prevalence of adverse pregnancy outcomes in pregnant women with

IBD exposed to TNF inhibitors is not greater than the general population while larger studies are needed to better evaluate the newest biologics, vedolizumab and ustekinumab

Our data also suggests that continued biologic therapy throughout the third trimester of pregnancy is not associated with increased risk of adverse pregnancy outcomes as compared to discontinuing biologics earlier on

Learn More – Primary Sources:

Biologics for Inflammatory Bowel Disease and their Safety in Pregnancy: A Systematic Review and Meta-analysis

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone, with ObGFirst

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Can Tighter Control Improve the Course of Crohn’s Disease?
Lithium Exposure: What are the Risks During Pregnancy?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site